AU2019283650A1 - Use of 5-((4-(2-(5-acetylpyridin-2-yl)ethoxy)benzyl)-1,3-thiazolidine-2,4-dione and its salts - Google Patents

Use of 5-((4-(2-(5-acetylpyridin-2-yl)ethoxy)benzyl)-1,3-thiazolidine-2,4-dione and its salts Download PDF

Info

Publication number
AU2019283650A1
AU2019283650A1 AU2019283650A AU2019283650A AU2019283650A1 AU 2019283650 A1 AU2019283650 A1 AU 2019283650A1 AU 2019283650 A AU2019283650 A AU 2019283650A AU 2019283650 A AU2019283650 A AU 2019283650A AU 2019283650 A1 AU2019283650 A1 AU 2019283650A1
Authority
AU
Australia
Prior art keywords
thiazolidine
ethoxy
phenyl
methyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019283650A
Other languages
English (en)
Inventor
Ana Maria GARCÍA COLLAZO
Marc Martinell Pedemonte
Maria Pilar Pizcueta Lalanza
Maria Angeles PÉREZ DE LA CRUZ MORENO
Estefania TRAVER LOPEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of AU2019283650A1 publication Critical patent/AU2019283650A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019283650A 2018-06-06 2019-06-06 Use of 5-((4-(2-(5-acetylpyridin-2-yl)ethoxy)benzyl)-1,3-thiazolidine-2,4-dione and its salts Abandoned AU2019283650A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382402.8 2018-06-06
EP18382402 2018-06-06
PCT/IB2019/054744 WO2019234690A1 (en) 2018-06-06 2019-06-06 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

Publications (1)

Publication Number Publication Date
AU2019283650A1 true AU2019283650A1 (en) 2021-01-07

Family

ID=62716011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019283650A Abandoned AU2019283650A1 (en) 2018-06-06 2019-06-06 Use of 5-((4-(2-(5-acetylpyridin-2-yl)ethoxy)benzyl)-1,3-thiazolidine-2,4-dione and its salts

Country Status (14)

Country Link
US (2) US20210228558A1 (enExample)
EP (1) EP3801517A1 (enExample)
JP (1) JP7510170B2 (enExample)
KR (1) KR20210031867A (enExample)
CN (1) CN112823004A (enExample)
AU (1) AU2019283650A1 (enExample)
BR (1) BR112020024939A2 (enExample)
CA (1) CA3102584A1 (enExample)
CL (1) CL2020003163A1 (enExample)
EA (1) EA202092954A1 (enExample)
IL (1) IL279186A (enExample)
MX (1) MX2020013182A (enExample)
SG (1) SG11202012095XA (enExample)
WO (1) WO2019234690A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
HUE071482T2 (hu) 2018-06-06 2025-08-28 Minoryx Therapeutics S L (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
CN116390725A (zh) * 2020-04-30 2023-07-04 米尼奥尔克斯治疗有限公司 用于治疗肺部炎症和间质性肺病的羟基吡格列酮
WO2022243435A1 (en) * 2021-05-19 2022-11-24 Abliva Ab Kl1333 for use in medicine
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3579049B2 (ja) 1992-04-30 2004-10-20 インスティチュート・パスツール Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓにおける抗生物質耐性の迅速検出法
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
AU2012203941A1 (en) * 2006-06-27 2012-07-26 Sandoz Ag New method for salt preparation
EP2436381A1 (en) * 2006-06-27 2012-04-04 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法

Also Published As

Publication number Publication date
CA3102584A1 (en) 2019-12-12
MX2020013182A (es) 2021-02-26
EA202092954A1 (ru) 2021-04-08
JP2021527061A (ja) 2021-10-11
SG11202012095XA (en) 2021-01-28
WO2019234690A1 (en) 2019-12-12
IL279186A (en) 2021-01-31
CL2020003163A1 (es) 2021-07-02
BR112020024939A2 (pt) 2021-03-09
US20240091210A1 (en) 2024-03-21
CN112823004A (zh) 2021-05-18
JP7510170B2 (ja) 2024-07-03
KR20210031867A (ko) 2021-03-23
EP3801517A1 (en) 2021-04-14
US20210228558A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US20240091210A1 (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
EP3125888B1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
US20250064791A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
WO2016153948A1 (en) Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
JP7549344B2 (ja) 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法
US11247970B2 (en) Selective inhibition of gluconeogenic activity
EP3548026B1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
US11572372B2 (en) Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds
EA047194B1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
HK40042762A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
HK40049546A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
EA047277B1 (ru) Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона
EP4323354B1 (en) 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted